XYTOS Clarifies and Defines Stock Issue and AvailabilityDue to Recent Inquiries
INDIANAPOLIS, Nov 03, 2008 (BUSINESS WIRE) -- XYTOS, Inc. (XYTS), the company called for an interior accounting of its stock issue due to recent inquiries and a recent spike in trading; and now posts its findings.
As of November 3, 2008 there are 26,268,000 outstanding XYTOS shares with approximately 6,500,000 shares outstanding and available for trading, commonly referred to as the float.
The balance of the shares are held in certificate form and are not available for sale; with 10 million of the shares restricted (r144) non-tradable securities.
Tim cook, Chairman and CEO of XYTOS, Inc., commented; "as we define our outstanding shares we continue to follow our business plan and we are making progress daily including our focus on listing XYTOS on the OTCBB and bringing XYTOS to a fully reporting status."
About XYTOS, Inc.
XYTOS working at the forefront of the "science of medicine" is a bio-medical technologies company concentrating on the research, development and introduction of next generation medicine and medical procedures in the areas of cancer, stem cell therapies, tissue engineering and cellular medicine. We invite all interested parties to review our website at http://www.xytos.com. Also look forward to upcoming announcements on our stem cell and tissue engineering bio-medical technologies.
On behalf of the Board of Directors of XYTOS Inc.
Tim Cook, CEO
SOURCE: XYTOS, Inc.
XYTOS Inc. Tim Cook, CEO, 317-815-1400 info@xytos.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.